
United Therapeutics (UTHR): Tyvaso Growth Meets Pipeline Catalysts
United Therapeutics combines a cash-rich balance sheet with record Tyvaso sales and multiple late-stage catalysts, but concentration in its flagship franchise keeps execution risk elevated. The stock looks fairly valued for a high-quality specialty biopharma with meaningful upside tied to 2027 regulatory decisions.






